TITLE:
One-Time Injection of Parathyrin Increases Glucose Tolerance
AUTHORS:
Svetlana Stepanovna Moisa, Alexander Danilovich Nozdrachev
KEYWORDS:
Parathyrin; Calcium Metabolism; Glucose Metabolism; Calcium Channel Blocker; Insulin Agonist; Glucose Tolerance; Glucoregulating Hormone
JOURNAL NAME:
Open Journal of Endocrine and Metabolic Diseases,
Vol.3 No.8,
December
25,
2013
ABSTRACT:
One-time injection of domestic preparation of bull parathyrin—parathyreoidin
(1 U/100g body weight, intramuscular) leads to a significant
decrease of the blood glucose level and an increase of the
serum calcium level in rats. There is a close negative correlation established
between glucose and calcium level (r = ?0.813, P > 0.02). The
calcium laktat load (9 mg) per os induces the same changes. There is a functional negative correlation established
between glucose levels and total calcium content (r = ?0.997, P 0.01). It
proves that the decrease of the blood glucose level under parathyrin
injection is connected with hypercalcaemia. Parathyrin causes the reduction of the
dynamics of hyperglycemia under the glucose load per os (30% solution, 1 ml/100g), i.e. parathyrin increases glucose tolerance. Glucose consumption by
muscle (diaphragm) and adipose (epididymal) tissues in vivo and in vitro does
not alter under parathyrin and it does not affect the stimulating effect of
insulin on the process. The combinative effect of parathyrin and calcium
channel blockers—isoptin (5 mg/kg, intraperitoneal) or nifedipin (1 mg/kg,
intraperitoneal) reveals more intensive and lasting decrease of the
blood glucose level in comparison with only parathyrin effect and more
reduction of the dynamics of hyperglycemia under the glucose load. Thus, parathyrin
decreases the blood glucose level, increases glucose tolerance and does not
effect insulin resistance.